Pelthos Therapeutics PTHS
NYSE PTHS
$20.45 +0.19 (+0.94%)
As of: Oct 20, 2026 · 3:52 PM EDT

Pelthos Therapeutics (PTHS) Gross Margin (2025 - 2026)

Updated

Pelthos Therapeutics (PTHS) reported Gross Margin of 76.86% for Q2 2026, down 7.80 percentage points from the prior quarter.

Analysis

Pelthos Therapeutics (PTHS) Gross Margin (2025 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Pelthos Therapeutics' Gross Margin came in at 78.59%; for FY2025, it came in at 76.25%.

  • Five-year quarterly Gross Margin spans a low of 68.73% in Q3 2025 and a high of 84.66% in Q1 2026.
  • Per Business Quant data, the three quarters before Q2 2026 came in at 84.66% (Q1 2026), 82.19% (Q4 2025) and 68.73% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn 85.78%
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn 68.19%
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn 74.74%
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn 73.54%
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn 78.02%
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn 83.60%
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn 72.04%
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn 79.76%
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn 72.78%
10 Pelthos Therapeutics 72.38 Mn -16.01 Mn 11.99 Mn 76.86%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 76.86%
Mar 31, 2026 84.66%
Dec 31, 2025 82.19%
Sep 30, 2025 68.73%
API Access

Pelthos Therapeutics Gross Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-margin&ticker=PTHS&period=max&api_key=YOUR_API_KEY